Navigation Links
Abbott Cuts Use of Oil and Coal by 35 Percent
Date:9/30/2009

nts around the world manufacturing pharmaceuticals, nutritional products and medical products, Abbott's opportunities to save electricity and utilize cleaner fuels vary based on the location and needs of its various manufacturing plants, as well as local availability of alternative energy sources. As a result, the company has exceeded its goal through a variety of projects including:

  • Co-generation -- In locations where its plants require a significant amount of steam, Abbott has invested in technology that produces both electricity and recycles waste heat to make steam. Abbott facilities powered in part by co-generation include pharmaceutical plants in Campoverde, Italy and Ludwigshafen, Germany. For example, in Campoverde, 85 percent of the plant's electric power demand is provided by co-generation.
  • Renewable energy -- Abbott has invested in renewable power sources, such as solar energy. Rooftop solar panels have been installed at Abbott's vascular product manufacturing facility in Temecula, Calif., commercial offices in Delkenheim, Germany and pharmaceutical manufacturing plants in Campoverde and Ludwigshafen. In one location, solar energy supplies 7 percent of the plant's electric power needs.
  • Energy efficient equipment -- Abbott is utilizing energy efficient equipment, such as lighting systems that require less electricity in Casa Grande, Ariz. and Des Plaines, Ill. Initiatives at other locations include high efficiency heating, ventilation and air conditioning systems, and variable frequency drives in plant equipment that provide only as much power as needed.

Looking to the future, Abbott continues to strive for reductions in electricity consumption and use of fossil fuels. Abbott businesses around the world are incorporating energy efficiency and use of cleaner fuels into new building design, and are implementing more than 10 new major energy-saving projects per year at exist
'/>"/>

SOURCE Abbott
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Abbott Receives Supplemental FDA Approval for its Best-in-Class in Sensitivity RealTime HIV-1 Viral Load Test
2. Abbott and AstraZeneca Announce Selection of Next-Generation Fenofibrate ABT-335 and CRESTOR(R) Fixed-Dose Combination
3. Abbott Initiates Clinical Study to Evaluate Use of RX Herculink(R) Elite(TM) Renal Stent System for the Treatment of Renal Artery Stenosis
4. Abbotts ABT-874 Shows Positive Results for Maintenance of Response in Phase II Psoriasis Study
5. Abbotts XIENCE(TM) V Everolimus Eluting Coronary Stent Shows Continued Superiority to TAXUS Stent in Reducing Major Adverse Cardiac Events in SPIRIT III Clinical Trial
6. Abbott Announces Positive One-Year Results from the Worlds First Clinical Trial of a Fully Bioabsorbable Drug Eluting Coronary Stent
7. Abbotts m2000(TM) Molecular Diagnostic Instrument and RealTime HIV-1 Test Win Chicago Innovation Award
8. Abbotts HUMIRA(R) (adalimumab) Receives FDA Approval For Moderate to Severe Chronic Plaque Psoriasis
9. Abbotts XIENCE(TM) V Drug Eluting Stent Demonstrates Consistent and Positive Clinical Outcomes Out to Two Years
10. Abbotts Phase III Studies of Investigational TriLipix(TM) (ABT-335), in Combination With Statins, Meets Primary Endpoints on Improving LDL, Triglycerides and HDL
11. Study in JAMA Shows Patients Treated With Abbotts XIENCE(TM) V Drug Eluting Stent Experience Better Outcomes Than Patients Treated With Market-Leading Drug Eluting Stent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... NEW YORK , Jan. 15, ... new market research report is available ... Global Markets and Technologies for ... on Routes of Administration ...
(Date:1/15/2014)...  A novel wearable injector slightly larger than an Oreo cookie ... self-inject prescription drugs in the large doses required to treat ... deficiencies, and genetic disorders.  An emerging biologic ... according to analysts.   Many of these drugs will require a ...
(Date:1/14/2014)... 2014  Luminex Corporation (Nasdaq: LMNX ) today announced ... of 2013 on Monday, February 3, 2014. A press release ... of trading. (Logo: http://photos.prnewswire.com/prnh/20100104/LUMINEXLOGO ) ... operating highlights and financial results for the fourth quarter and ...
Breaking Medicine Technology:Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 16Enable Injections Presents A New Class of Injectors for Drug Delivery at PEPTalk, Drug Delivery Partnership Meetings 2Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 2Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 3
(Date:4/17/2014)... -- The world is less than 40 years away ... for people and governments, according to a top scientist ... first time in human history, food production will be ... land, water and energy," said Dr. Fred Davies, senior ... "Food issues could become as politically destabilizing by 2050 ...
(Date:4/17/2014)... 17, 2014While 94 per cent of Canadians surveyed said ... newborns for a specific number of genetic conditions, only ... participate in screening that would sequence their newborns, genomes.,Most ... in their first day or two of life in ... their heels and tested for about five to 54 ...
(Date:4/17/2014)... Vice-Chancellor, Professor Patrick Johnston, whose work has transformed cancer ... Fellow of the European Academy of Cancer Sciences., The ... advisory body of highly distinguished oncologists and cancer researchers ... by cancer in Europe. , Professor Johnston, whose leadership ... from the bottom of the UK league table to ...
(Date:4/17/2014)... from LSTM have called for more research to ... in children in sub-Saharan Africa. In a paper ... Professor Russell Stothard, working with colleagues in the ... Reserve University, in Cleveland Ohio, University of Cambridge ... research into the joint burden of HIV/AIDS and ...
(Date:4/16/2014)... April 15, 2014 The Translational Genomics Research ... their annual Founders Dinner for their support of TGen,s ... took place March 28 in Scottsdale. , Catherine Ivy, ... Foundation, received TGen,s John S. McCain Leadership Award, named ...
Breaking Medicine News(10 mins):Health News:Food shortages could be most critical world issue by mid-century 2Health News:Researcher looks at public perceptions around newborn testing 2Health News:Researcher looks at public perceptions around newborn testing 3Health News:More research called for into HIV and schistosomiasis coinfection in African children 2Health News:TGen honors Catherine Ivy and Craig Jackson with Leadership; Collaborative Spirit awards 2
... 2011 Metabolomx, a diagnostic company focused on the ... breath, today announces publication of results from the first ... detect lung cancer and differentiate between types of lung ... the Cleveland Clinic and led by Dr. Peter Mazzone, ...
... patients in a New England Journal of Medicine ... recovered from hip surgery, according to new research co-authored ... findings could immediately change the way such patients are ... strengthen patients weakened by anemia, improving their chances at ...
... been diagnosed with locally-advanced pancreatic cancer in the United ... for these patients whose tumor has grown beyond the ... 20 years, numerous treatment regimens have been evaluated for ... being the current standard approach. However, the median survival ...
... , WEDNESDAY, Dec. 14 (HealthDay News) -- Alcohol ... more of them are using marijuana and don,t believe it,s ... by the U.S. National Institute on Drug Abuse and the ... students in grades eight, 10 and 12 at 400 public ...
... Amanda Gardner HealthDay Reporter , WEDNESDAY, Dec. 14 ... cholesterol levels, may one day also prove useful in combating ... the Journal of Infectious Diseases finds that patients ... were taking a statin, compared with their peers who weren,t ...
... News) -- In the aftermath of a deadly crash in ... Transportation Safety Board is recommending a nationwide ban on drivers, ... emergencies. According to media reports, the board was meeting ... occurred last year in Gray Summit, Mo. The NTSB ...
Cached Medicine News:Health News:Metabolomx test detects lung cancer from breath 2Health News:Metabolomx test detects lung cancer from breath 3Health News:University of Maryland finds restricting post-surgery blood transfusion is safe for some hip patients 2Health News:University of Maryland finds restricting post-surgery blood transfusion is safe for some hip patients 3Health News:RTOG initiates a phase I trial testing the therapy ganitumab for locally advanced pancreatic cancer 2Health News:Alcohol Use Down, Pot Use Up Among U.S. Teens 2Health News:Could Statins Help Those Hospitalized With Flu? 2Health News:U.S. Safety Board Urges Nationwide Ban on Drivers' Use of Cellphones 2
This lens gives the appearance of mystery and mayhem behind the blackest of eyes....
Silicone tip cannula angled at 7 mm, sterile, disposable (bx/10)....
Medpor Sphere Inserter. The Inserter is provided as a value added item to Medpor Orbital Implants....
Reusable cannula with .90 mm (20 g) shaft, tapering to .30 mm (30 g). Angled 125 3 mm from tip and flattened for easy insertion into the subretinal space....
Medicine Products: